XTX Topco’s Soleno Therapeutics SLNO Stock Holding History

XTX Topco’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-85,680	Closed	-$2.87M	–	4665
2026 Q1	$2.87M	Buy	85,680 +49,386	+136%	+$1.94M	0.05%	589
2025 Q4	$1.68M	Buy	+36,294	New	+$1.99M	0.04%	679
2025 Q2	–	Sell	-23,105	Closed	-$1.65M	–	3098
2025 Q1	$1.65M	Buy	23,105 +16,813	+267%	+$819K	0.08%	321
2024 Q4	$283K	Buy	+6,292	New	+$326K	0.02%	1278
2021 Q3	–	Sell	-1,665	Closed	-$28K	–	1032
2021 Q2	$28K	Buy	1,665 +471	+39%	+$7.96K	0.01%	754
2021 Q1	$23K	Buy	+1,194	New	+$38.5K	0.01%	654

XTX Topco's SLNO Position: Q2 2026 in Review

XTX Topco sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 85,680 shares — an estimated $2.87M sold.

XTX Topco first reported a position in SLNO in Q1 2021 and held it in 6 quarters. The position peaked at $2.87M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

XTX Topco reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 85,680 Soleno Therapeutics shares in Q2 2026, an estimated $2.87M.
XTX Topco first reported a position in Soleno Therapeutics in Q1 2021 and held it in 6 quarters.
XTX Topco's Soleno Therapeutics position peaked at $2.87M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.